Similar to our findings, clinical trials evaluating DPP4 inhibitors have reported a significant reduction in fibrosis scores and liver enzymes (AST and ALT levels) in NAFLD patients without diabetes [42,43]. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.